Novartis is poised to broaden the therapeutic landscape for chronic inducible urticaria (CINDU) with its oral BTK inhibitor, Rhapsido (remibrutinib). Following a successful phase 3 trial, the Swiss pharmaceutical giant is on track to secure an expanded label for this innovative treatment, highlighting its efficacy in managing various forms of CINDU.
Understanding CINDU
CINDU encompasses a group of chronic skin disorders that affect approximately 0.5% of the global population, translating to about 29 million cases worldwide. Patients with CINDU experience hives or swelling triggered by physical stimuli. The three primary forms of CINDU include symptomatic dermographism, cold urticaria, and cholinergic urticaria, each precipitated by distinct environmental factors. For instance, cold urticaria is often triggered by exposure to low temperatures, while dermographism can result from friction or light scratching of the skin.
Rhapsido’s Efficacy and Approval
Rhapsido has already received approval for treating chronic spontaneous urticaria (CSU), a condition where patients suffer from hives without identifiable triggers, and is estimated to affect about 1% of the global population. Novartis has reported that Rhapsido significantly outperforms placebo in achieving complete response rates in the most common forms of CINDU, as evidenced by the RemIND trial, which included 364 patients whose symptoms were unmanageable with antihistamines.
The findings signal a potential breakthrough in targeted therapies for CINDU, a condition traditionally managed through avoidance of triggers and the use of second-generation antihistamines. Current off-label treatments include Roche’s anti-IgE antibody, Xolair (omalizumab). With Rhapsido, Novartis may offer a more effective, targeted approach to treatment.
Future Regulatory Filings
Novartis has already initiated the approval process for Rhapsido concerning symptomatic dermographism, the predominant form of CINDU. The company plans to submit additional filings for all three forms of CINDU globally in the forthcoming months. If successful, Rhapsido could become the first targeted therapy specifically approved for these conditions.
Competitive Landscape
This new indication for Rhapsido could strategically position Novartis in a niche market, minimizing competition with major players like Sanofi and Regeneron. Their product, Dupixent (dupilumab), has achieved significant success in treating CSU but has yet to receive approval for CINDU. While Sanofi previously explored Dupixent for CINDU, it has shifted focus to another candidate, the KIT inhibitor SAR449028, which is currently in phase 2 testing.
Market Potential
Rhapsido received FDA approval in September and began market rollout shortly thereafter. Although Novartis has yet to disclose specific sales figures, early signs of uptake among CSU patients resistant to antihistamines are promising. The company’s CEO, Vas Narasimhan, expressed optimism about Rhapsido’s potential, noting that it could become one of Novartis’s most significant brands in history.
Key Takeaways
- Rhapsido shows superior efficacy in treating the most common forms of CINDU compared to placebo.
-
Novartis plans to expand Rhapsido’s indication for symptomatic dermographism and other CINDU forms globally.
-
This development places Novartis in a favorable position, largely free from competition in the CINDU market.
-
Early market uptake indicates strong potential for Rhapsido, aligning with successful dermatology product launches.
In conclusion, Novartis’s strategic advancements with Rhapsido signify a promising shift in the management of chronic inducible urticaria. As the company moves forward with regulatory submissions, the healthcare community and patients alike eagerly anticipate the broader availability of this important therapy. The potential impact on patient care could be transformative, filling a significant gap in the current treatment landscape.
Read more → pharmaphorum.com